Thulium Laser and Growth Factors for Androgenetic Alopecia

Recruiting now · Not applicable

Conditions studied: Androgenetic Alopecia (AGA)

In brief

Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity. Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.

Key facts

Study ID

NCT07079657

Run by

Universitätsklinikum Hamburg-Eppendorf

People needed

30

Starts

2023-12-01

Expected to finish

2025-10-01

Last updated by the study team

2025-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women aged 18 and over
• Good general health, no relevant previous illnesses
• Presence of an AGA
• Cognitive ability and willingness to give consent (informed consent)
• Be willing and able to attend follow-up visits

You may not qualify if…

• Age < 18 years
• Pregnant or breastfeeding women
• Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs
• Significant scarring of the region to be treated
• Significant open wounds or lesions in the region to be treated
• Metallic implants in the head region
• Mental illnesses (psychoses, body perception disorders)
• Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks
• Resurfacing (fractional, ablative, non-ablative) of the affected region < 2 months before and during the study period
• Tendency to excessive scarring
• Lack of informed consent and/or data protection declarations

Where it is running

• University Medical Center Hamburg-Eppendorf — Hamburg, Free and Hanseatic City of Hamburg, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.